NCT07502456

Brief Summary

The purpose of this research study is to generate safety and performance data for Clareon TruPlus Monofocal Intraocular Lenses (IOLs). IOLs are medical devices that are implanted in the eye during cataract surgery to restore clear vision after the cloudy natural lens has been removed. IOLs are intended to remain in the eyes for the duration of the patient's lifetime.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
122

participants targeted

Target at P50-P75 for not_applicable

Timeline
23mo left

Started May 2026

Typical duration for not_applicable

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
May 2026Jun 2028

First Submitted

Initial submission to the registry

March 26, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 31, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

May 26, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2028

Last Updated

June 3, 2026

Status Verified

June 1, 2026

Enrollment Period

2 years

First QC Date

March 26, 2026

Last Update Submit

June 1, 2026

Conditions

Keywords

Cataract

Outcome Measures

Primary Outcomes (1)

  • Mean Binocular Photopic Best Corrected Distance Visual Acuity (BCDVA)

    Visual acuity (VA) will be assessed binocularly (both eyes together) with correction in place under photopic (well-lit) conditions at a distance of 4 meters. BCDVA will be measured using letter charts and recorded in logarithm of the Minimum Angle of Resolution (logMAR). The LogMAR VA scale ranges from -0.30 (20/10 Snellen) to 1.00 (20/200 Snellen). A LogMAR value of 0 equates to 20/20 Snellen VA (normal distance eyesight), with negative LogMAR values representing better than 20/20 VA. Subjects with at least one implanted eye with a toric IOL will be categorized as toric as specified in the statistical analysis plan. No hypothesis testing is pre-specified for this endpoint

    Day 0 preoperative, Month 1, Month 3, Month 12

Study Arms (1)

Clareon TruPlus Monofocal IOL

EXPERIMENTAL

Implantation with the Clareon TruPlus Monofocal IOL (Non-Toric or Toric) following removal of the clouded natural lens using phacoemulsification

Device: Clareon TruPlus Monofocal Non-Toric IOLDevice: Clareon TruPlus Monofocal Toric IOLProcedure: Phacoemulsification

Interventions

Monofocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia in adult patients. The Clareon TruPlus IOL is designed to maintain distance image quality while slightly extending the depth of focus compared to standard monofocal IOLs.

Also known as: Models REYWT0, REYAT0, RECWT0, RECAT0
Clareon TruPlus Monofocal IOL

Monofocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia and pre-existing corneal astigmatism. The Clareon TruPlus IOL is designed to maintain distance image quality while slightly extending the depth of focus compared to standard monofocal IOLs.

Also known as: Models REYWT3, REYWT4, REYWT5, REYAT3, REYAT4, REYAT5, RECWT3, RECWT4, RECWT5, RECAT3, RECAT4, RECAT5.
Clareon TruPlus Monofocal IOL

Minimally invasive surgery technique that utilizes ultrasonic vibrations to break up (emulsify) and remove a cloudy lens through a small, self-sealing, 2-3mm incision

Clareon TruPlus Monofocal IOL

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with bilateral cataracts and planned bilateral cataract extraction by routine phacoemulsification.
  • Potential postoperative BCDVA of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.
  • Astigmatism suitable for correction with available toric IOL models.

You may not qualify if:

  • Age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and other eye conditions as specified in the protocol.
  • Moderate to severe dry eye that would affect study measurements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Eye Doctors of Arizona

Phoenix, Arizona, 85028, United States

RECRUITING

Cleveland Eye Clinic

Brecksville, Ohio, 44141, United States

RECRUITING

Carolina Eyecare Physicians LLC

Mt. Pleasant, South Carolina, 29464, United States

RECRUITING

Berkeley Eye Center

Sugar Land, Texas, 77478, United States

RECRUITING

The Eye Institute of Utah

Salt Lake City, Utah, 84107, United States

RECRUITING

MeSH Terms

Conditions

AphakiaAstigmatismCataract

Interventions

Phacoemulsification

Condition Hierarchy (Ancestors)

Lens DiseasesEye DiseasesRefractive Errors

Intervention Hierarchy (Ancestors)

Cataract ExtractionRefractive Surgical ProceduresOphthalmologic Surgical ProceduresSurgical Procedures, OperativeUltrasonic Surgical Procedures

Study Officials

  • Clinical Trial Lead, Surgical

    Alcon Research, LLC

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 26, 2026

First Posted

March 31, 2026

Study Start

May 26, 2026

Primary Completion (Estimated)

June 1, 2028

Study Completion (Estimated)

June 1, 2028

Last Updated

June 3, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations